113 related articles for article (PubMed ID: 18034621)
1. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.
Etienne-Grimaldi MC; Francoual M; Formento JL; Milano G
Pharmacogenomics; 2007 Nov; 8(11):1561-6. PubMed ID: 18034621
[TBL] [Abstract][Full Text] [Related]
2. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
Etienne MC; Formento JL; Chazal M; Francoual M; Magné N; Formento P; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
Pharmacogenetics; 2004 Dec; 14(12):785-92. PubMed ID: 15608557
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
4. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
Marcuello E; Altés A; Menoyo A; Rio ED; Baiget M
Cancer Chemother Pharmacol; 2006 Jun; 57(6):835-40. PubMed ID: 16187112
[TBL] [Abstract][Full Text] [Related]
5. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.
Afzal S; Jensen SA; Vainer B; Vogel U; Matsen JP; Sørensen JB; Andersen PK; Poulsen HE
Ann Oncol; 2009 Oct; 20(10):1660-6. PubMed ID: 19465420
[TBL] [Abstract][Full Text] [Related]
6. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
[TBL] [Abstract][Full Text] [Related]
7. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
8. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.
Sohn KJ; Croxford R; Yates Z; Lucock M; Kim YI
J Natl Cancer Inst; 2004 Jan; 96(2):134-44. PubMed ID: 14734703
[TBL] [Abstract][Full Text] [Related]
9. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
Afzal S; Gusella M; Vainer B; Vogel UB; Andersen JT; Broedbaek K; Petersen M; Jimenez-Solem E; Bertolaso L; Barile C; Padrini R; Pasini F; Jensen SA; Poulsen HE
Clin Cancer Res; 2011 Jun; 17(11):3822-9. PubMed ID: 21471424
[TBL] [Abstract][Full Text] [Related]
10. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Cohen V; Panet-Raymond V; Sabbaghian N; Morin I; Batist G; Rozen R
Clin Cancer Res; 2003 May; 9(5):1611-5. PubMed ID: 12738713
[TBL] [Abstract][Full Text] [Related]
11. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.
Gusella M; Frigo AC; Bolzonella C; Marinelli R; Barile C; Bononi A; Crepaldi G; Menon D; Stievano L; Toso S; Pasini F; Ferrazzi E; Padrini R
Br J Cancer; 2009 May; 100(10):1549-57. PubMed ID: 19384296
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Yeh CC; Lai CY; Chang SN; Hsieh LL; Tang R; Sung FC; Lin YK
Int J Clin Oncol; 2017 Jun; 22(3):484-493. PubMed ID: 28044213
[TBL] [Abstract][Full Text] [Related]
13. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes.
Pardini B; Kumar R; Naccarati A; Novotny J; Prasad RB; Forsti A; Hemminki K; Vodicka P; Lorenzo Bermejo J
Br J Clin Pharmacol; 2011 Jul; 72(1):162-3. PubMed ID: 21204909
[No Abstract] [Full Text] [Related]
14. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer.
Ma J; Stampfer MJ; Giovannucci E; Artigas C; Hunter DJ; Fuchs C; Willett WC; Selhub J; Hennekens CH; Rozen R
Cancer Res; 1997 Mar; 57(6):1098-102. PubMed ID: 9067278
[TBL] [Abstract][Full Text] [Related]
15. Associations between two common variants C677T and A1298C in the methylenetetrahydrofolate reductase gene and measures of folate metabolism and DNA stability (strand breaks, misincorporated uracil, and DNA methylation status) in human lymphocytes in vivo.
Narayanan S; McConnell J; Little J; Sharp L; Piyathilake CJ; Powers H; Basten G; Duthie SJ
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1436-43. PubMed ID: 15342443
[TBL] [Abstract][Full Text] [Related]
16. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
[TBL] [Abstract][Full Text] [Related]
17. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
18. The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase.
Kawakami K; Ruszkiewicz A; Bennett G; Moore J; Watanabe G; Iacopetta B
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5860-5. PubMed ID: 14676107
[TBL] [Abstract][Full Text] [Related]
19. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
De Mattia E; Toffoli G
Eur J Cancer; 2009 May; 45(8):1333-51. PubMed ID: 19144510
[TBL] [Abstract][Full Text] [Related]
20. Role of the MTHFR polymorphisms in cancer risk modification and treatment.
Kim YI
Future Oncol; 2009 May; 5(4):523-42. PubMed ID: 19450180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
